Elementis
ELM · Main Market · Chemicals · mcap £1,030m · 181.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 12 Oct 26 | Routine | Transaction in Own Shares | |
| 05 Oct 26 | Routine | Transaction in Own Shares | |
| 28 Sep 26 | Routine | Transaction in Own Shares | |
| 21 Sep 26 | Routine | Transaction in Own Shares | |
| 16 Sep 26 | Director dealing | Director/PDMR Shareholding | |
| 16 Sep 26 | Appointment of Senior Independent Director
Christine Soden appointed Senior Independent Director, having held the interim role since March 2026. |
+1.3% | |
| 14 Sep 26 | Routine | Transaction in Own Shares | |
| 07 Sep 26 | Routine | Transaction in Own Shares | |
| 01 Sep 26 | Routine | Transaction in Own Shares | |
| 24 Aug 26 | Routine | Transaction in Own Shares | |
| 17 Aug 26 | Routine | Transaction in Own Shares | |
| 10 Aug 26 | Routine | Transaction in Own Shares | |
| 03 Aug 26 | Routine | Transaction in Own Shares | |
| 30 Jul 26 | Holding | Holding(s) in Company | |
| 30 Jul 26 | Additional Directorship Declaration
Pursuant to UK Listing Rule 6.4.9R, the Company announces that Christopher Mills was appointed as a non-executive director of Aquila European Renewables plc from 21 May 2026. |
+1.5% | |
| 30 Jul 26 | Results | Half-year Results
H1 26 revenue up 4.7% organic, adjusted operating profit up 16.4%, margins expanded to 23.0%. |
+1.5% |
| 27 Jul 26 | Routine | Transaction in Own Shares | |
| 20 Jul 26 | Routine | Transaction in Own Shares | |
| 13 Jul 26 | Routine | Transaction in Own Shares | |
| 06 Jul 26 | Routine | Transaction in Own Shares | |
| 01 Jul 26 | Routine | Total Voting Rights | |
| 29 Jun 26 | Routine | Transaction in Own Shares | |
| 22 Jun 26 | Routine | Transaction in Own Shares | |
| 22 Jun 26 | Routine | Transaction in Own Shares | |
| 15 Jun 26 | Routine | Transaction in Own Shares | |
| 08 Jun 26 | Routine | Transaction in Own Shares | |
| 03 Jun 26 | Commencement of share buyback programme
Elementis commences £25m share buyback programme, running until 28 February 2027. |
−2.2% | |
| 02 Jun 26 | Sale of Pharma business & intended buyback launch
Elementis completes sale of pharma business to ABF for €34.3m and launches c.$35m buyback programme. |
+2.9% | |
| 01 Jun 26 | Routine | Total Voting Rights | |
| 05 May 26 | Holding | Holding(s) in Company | |
| 01 May 26 | Routine | Total Voting Rights | |
| 29 Apr 26 | Routine | Result of AGM | |
| 29 Apr 26 | Trading update | First quarter trading update
Q1 organic revenue growth of c.2% with profit and margin expansion; full year outlook unchanged. |
−0.9% |
| 08 Apr 26 | Director dealing | Director/PDMR Shareholding | |
| 07 Apr 26 | Director dealing | Director/PDMR Shareholding | |
| 01 Apr 26 | Routine | Total Voting Rights | |
| 30 Mar 26 | Correction - Admission to Trading
Correction to admission of 2,000,000 LTIP shares to trading on Main Market. |
+0.7% | |
| 30 Mar 26 | Routine | Admission to Trading | |
| 26 Mar 26 | Routine | Notice of AGM and Annual Report & Accounts | |
| 19 Mar 26 | Board change | Directorate Change
Trudy Schoolenberg appointed Non-Executive Chair from 29 April 2026, Mike Humphrey joins as Non-Executive Director. |
−5.0% |
| 11 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 10 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 10 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 09 Mar 26 | Holding | Holding(s) in Company | |
| 05 Mar 26 | Routine | Blocklisting Interim Review | |
| 05 Mar 26 | Results | Preliminary Results - Correction
FY2025 results show resilient performance with adjusted operating profit up 4.6% and dividend raised 7.5%. |
−0.5% |
| 05 Mar 26 | Results | Final Results
FY25 adjusted operating profit up 4.6% to $126.7m; pharma business sale to ABF agreed for Q2 2026 completion. |
−0.5% |
| 02 Mar 26 | Routine | Total Voting Rights | |
| 25 Feb 26 | Board change | Directorate Change
Non-executive director Dorothee Deuring retiring from the Board after nine years. |
−2.0% |
| 02 Feb 26 | Routine | Total Voting Rights | |
| 21 Jan 26 | Trading update | Trading Update
Full year revenues in line with consensus, adjusted operating profit marginally ahead with improved margins. |
+1.6% |
| 02 Jan 26 | Routine | Total Voting Rights | |
| 02 Jan 26 | Confirmation of Board changes
Further to the announcement on 30 September 2025, the Company confirms that Kath Kearney-Croft has taken up the role as Chief Financial Officer with effect from 1 January 2026, and Ralph Hewins has stepped down from that |
+0.4% | |
| 24 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 15 Dec 25 | Completion of Buyback programme
Elementis completed £40.0m share buyback programme, cancelling 4.15% of issued share capital. |
−1.0% | |
| 15 Dec 25 | Routine | Transaction in Own Shares | |
| 11 Dec 25 | Routine | Transaction in Own Shares | |
| 10 Dec 25 | Routine | Transaction in Own Shares | |
| 09 Dec 25 | Routine | Transaction in Own Shares | |
| 08 Dec 25 | Routine | Transaction in Own Shares | |
| 08 Dec 25 | Routine | Transaction in Own Shares | |
| 04 Dec 25 | Routine | Transaction in Own Shares | |
| 03 Dec 25 | Routine | Transaction in Own Shares | |
| 03 Dec 25 | Routine | Transaction in Own Shares | |
| 01 Dec 25 | Routine | Transaction in Own Shares | |
| 28 Nov 25 | Routine | Transaction in Own Shares | |
| 27 Nov 25 | Routine | Transaction in Own Shares | |
| 27 Nov 25 | Routine | Transaction in Own Shares | |
| 26 Nov 25 | Elementis acquires personal care specialist
Elementis completes acquisition of personal care specialist Alchemy Ingredients for approximately $22m enterprise value. |
+0.8% | |
| 25 Nov 25 | Routine | Transaction in Own Shares | |
| 24 Nov 25 | Routine | Transaction in Own Shares | |
| 21 Nov 25 | Routine | Transaction in Own Shares | |
| 21 Nov 25 | Director dealing | Director/PDMR Shareholding | |
| 20 Nov 25 | Routine | Transaction in Own Shares | |
| 19 Nov 25 | Routine | Transaction in Own Shares | |
| 18 Nov 25 | Routine | Transaction in Own Shares | |
| 17 Nov 25 | Routine | Transaction in Own Shares | |
| 14 Nov 25 | Routine | Transaction in Own Shares | |
| 13 Nov 25 | Routine | Transaction in Own Shares | |
| 12 Nov 25 | Routine | Transaction in Own Shares | |
| 11 Nov 25 | Routine | Transaction in Own Shares | |
| 10 Nov 25 | Routine | Transaction in Own Shares | |
| 07 Nov 25 | Routine | Transaction in Own Shares | |
| 06 Nov 25 | Routine | Transaction in Own Shares | |
| 05 Nov 25 | Routine | Transaction in Own Shares | |
| 04 Nov 25 | Routine | Transaction in Own Shares | |
| 03 Nov 25 | Routine | Transaction in Own Shares | |
| 31 Oct 25 | Routine | Transaction in Own Shares | |
| 30 Oct 25 | Routine | Transaction in Own Shares | |
| 29 Oct 25 | Routine | Transaction in Own Shares | |
| 29 Oct 25 | Trading update | Third Quarter Trading Update
Q3 revenue £152m flat year-on-year; full year guidance maintained; CEO and chair transitions announced. |
−3.4% |
| 28 Oct 25 | Routine | Transaction in Own Shares | |
| 27 Oct 25 | Routine | Transaction in Own Shares | |
| 24 Oct 25 | Routine | Transaction in Own Shares | |
| 23 Oct 25 | Routine | Transaction in Own Shares | |
| 22 Oct 25 | Routine | Transaction in Own Shares | |
| 21 Oct 25 | Routine | Transaction in Own Shares | |
| 20 Oct 25 | Routine | Transaction in Own Shares | |
| 17 Oct 25 | Routine | Transaction in Own Shares | |
| 16 Oct 25 | Routine | Transaction in Own Shares | |
| 15 Oct 25 | Routine | Transaction in Own Shares | |
| 15 Oct 25 | Routine | Correction - Transaction in Own Shares | |
| 14 Oct 25 | Routine | Transaction in Own Shares | |
| 13 Oct 25 | Routine | Transaction in Own Shares | |
| 10 Oct 25 | Routine | Transaction in Own Shares | |
| 09 Oct 25 | Routine | Transaction in Own Shares | |
| 08 Oct 25 | Routine | Transaction in Own Shares | |
| 07 Oct 25 | Routine | Transaction in Own Shares | |
| 06 Oct 25 | Routine | Transaction in Own Shares |
Company filings. Not investment advice.